Current updates in the Medical Management of Obesity

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 2, 2012, Pages 117-128

  Khan, Areej ^a   Raza, Shahzad ^a   Khan, Yusra ^b   Aksoy, Tulay ^b   Khan, Monis ^c   Weinberger, Yitzchak ^a   Goldman, Joel ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Exenatide; Metabolic syndrome; Orlistat; Phentermine; Pramlintide; Topiramate

Indexed keywords

AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; ANTI GHRELIN VACCINE; ANTIOBESITY AGENT; CETILISTAT; ESTRONE OLEATE; EXENDIN 4; FENFLURAMINE; GT 389255; HORMONE RECEPTOR BLOCKING AGENT; HUMAN GROWTH HORMONE[176-191][176 TYROSINE]; LORCASERIN; MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST; MELANOCORTIN 4 RECEPTOR ANTAGONIST; METFORMIN; MK 0493; NALTREXONE; OBINEPITIDE; OXYNTOMODULIN; PEPTIDE YY [3-36]; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VACCINE; ZONISAMIDE;

ABDOMINAL PAIN; ABNORMAL THINKING; AGGRESSION; AGITATION; ALLERGIC REACTION; AMBLYOPIA; ANOREXIA; ANXIETY; ARTHRITIS; ARTICLE; BIRTH DEFECT; BLEEDING; BODY MASS; BRONCHITIS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONSTIPATION; DECREASED APPETITE; DEFECATION; DEPRESSION; DIARRHEA; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; INTERSTITIAL NEPHRITIS; IRRITABILITY; LACTIC ACIDOSIS; LEG CRAMP; LIFESTYLE MODIFICATION; LOOSE FECES; MEMORY DISORDER; MENSTRUATION DISORDER; METABOLIC SYNDROME X; MORTALITY; MUSCLE HYPERTONIA; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PATIENT CARE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; QT INTERVAL; RISK REDUCTION; SEIZURE; SIDE EFFECT; SUICIDAL IDEATION; SWEATING; TOOTH DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

EID: 84861777601     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412800604644     Document Type: Article

References (85)

1. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; (3): 004-094.
2. International Obesity Task Force. Global obesity map. Available at: http: //www.iotf.org/database/documents/ GlobalAdultmapswith- top5ineachregion000.ppt. (Accessed on: January 18, 2007).
3. Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 2010; 10 (5): 321-334.
4. World Health Organisation (WHO). Obesity: Preventing and managing the Global Epidemic - Report of a WHO Consultation on Obesity, 3-5 June 1997. WHO/NUT/NCD/98.1 1998.
5. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin, EJ, Larson MG, et al. Obesity and risk of heart failure. N Engl J Med 2002; 347(5): 305-13.
6. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Bodymass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341(15): 1097-105
7. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338(1): 1-7.
8. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 (1): 004-096.
9. King H, Aubert RE, Herman WH. Global Burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414-31.
10. Gade W, Schmit J, Collins M, Gade J. Beyond obesity: The diagnosis and pathophysiology of metabolic syndrome. Clin Lab Sci 2010; 23(1): 51-61.
11. Zimmett P, Thomas CR. Genotype, obesity and cardiovascular disease-has technical and social advancement outstripped evolution? J Intern Med 2003; 254 (2): 114-25J.
12. Unger RH. Longevity, lipotoxicity and leptin: The adipocyte defense against feasting and famine. Biochimie 2005; 87(1): 57-64.
13. The World Health Organization Report. Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization. Available at: www.who.int/entity/whr/2002/Overview_E.pdf (Accessed on: October 1, 2002).
14. Lau DCW. Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007; 176(8): 1103-6.
15. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000; 356(9248): 2119-25.
16. Gokcel A, Gumurdulu Y, Karakose H, Melek EE, Tanaci N, Bascil TN, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4(1): 49-55.
17. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord 2004; 28(4): 600-605.
18. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002; 19: 119-24.
19. Choussein S, Makri AA, Frangos CC, Petridou ET, Daskalopoulou SS. Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11(7): 641-64.
20. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005; 22(5): 612-618.
21. Chou KM, Huang BY, Fanchiang JK, Chen CH. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients. Chang Gung Med J 2007; 30(6): 538-546.
22. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004; 17(4): 222-229.
23. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25 (9): 1123-1128.
24. Shi YF, Pan CY, Hill J, Gao Y. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabet Med 2005; 22 (12): 1737-1743.
25. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumor necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003; 5(3): 195-201.
26. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: A critical review. Drug Saf 2008; 31(1): 53-65.
27. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomized controlled study. Lancet 2006; 368: 1660-72.
28. Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011; 2(2): 19-23.
29. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377(9774): 1341-52.
30. FDA rejects second weight-loss drug in a week msnbc.com news services. http://www.msnbc.msn.com/id/39905030/ns/health- diet_and_nutrition/. (Accessed on: October 29, 2010).
31. Najarian, T., Tam, P., Wilson, L. Low dose topiramate/phentermine composition and methods of use thereof. US20110262535 (2011).
32. Holman RR, Paul SK, Bethal MA, Matthews DR, Neil AW. 10- Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 (15): 1577-89.
33. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89 (9): 4588-93.
34. Shaker M, Mashhadani ZI, Mehdi AA. Effect of treatment with metformin on omentin-1, ghrelin and other biochemical, clinical features in PCOS patients. Oman Med J 2010; 25 (4): 289-93.
35. Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2011; doi: 10.1111/j.1463- 1326.2011.01530.x.
36. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333 (9): 541-9.
37. Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: A systematic review and meta-analysis. J Psychopharmacol 2011; 25 (3): 299-305.
38. Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier? Pharmacol Biochem Behav 2010; 97(1): 63-83.
39. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009; 17 (1): 30-9.
40. Garber A. Glucagon-like peptide-1-based therapies: New developments and emerging data. Diabetes Obes Metab 2008; 10: 22-35.
41. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006; 29 (2): 435-49.
42. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel- group study. Clin Ther 2008; 30 (8): 1448-60.
43. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11): 2628-35.
44. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebocontrolled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010; 86(1): 44-57.
45. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33(6): 1173-5.
46. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo controlled study. Lancet 2009; 374(9701): 1606-16.
47. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(1): 275-286.
48. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123(5): 468-917.
49. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010; 33(8): 1734-1737.
50. Clemens, A.H. Method of restoring the incretin effect. US7893080 (2011).
51. Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 2005; 6(2): 181-9.
52. Lutz TA. Amylinergic control of food intake. Physiol Behav 2006; 89(4): 465-71.
53. Folli F, Guardado-Mendoza R. Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs 2011; 20(12): 1717-22.
54. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12(4): 661-8.
55. Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW. Twentyfour-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J Clin Endocrinol Metab 2009; 94(5): 1608-11.
56. Kishiyama CM, Burdick PL, Cobry EC, Gage VL, Messer LH, McFann K, et al. A pilot trial of pramlintide home usage in adolescents with type 1 diabetes. Pediatrics 2009; 124(5): 1344-7.
57. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25(4): 724-30.
58. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabet Med 2004; 21: 1204-12.
59. Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother 2010; 44(3): 538-45.
60. Duft, B.J. Methods for treating obesity. US7910548 (2011).
61. Lam DD, Przydzial MJ, Ridley SH, Yeo GS, Rochford JJ, O'Rahilly S, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008; 149(3): 1323-1328.
62. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, et al. Lorcaserin (APD356), a selective 5-HT (2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009; 17(3): 494-503.
63. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363(3): 245-56.
64. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab 2011; 96(10): 3067-3077.
65. Smith, J. 5HT2C receptor modulators. US977329 (2011).
66. McBride R. "Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation". Xconomy Boston. Availabe at: http://www.xconomy.com/boston/2011/03/23/genzyme-spinout-peptimmune-files-for-chapter-7-liquidation (Accessed on: September 5, 2011).
67. Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, et al. Cetilistat (ATL-962), a novel lipase inhibitor: A 12- week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007; 31(3): 494-499.
68. Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: Comparison with orlistat (Xenical). Obesity (Silver Spring) 2010; 18(1): 108-15.
69. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway- Campbell B, Waters MJ, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or amodified C-terminal fragment. Int J Obes Relat Metab Disord 2001; 25: 1442-1449.
70. Tuntland, D.S. Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring. US7605122 (2009).
71. Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M. Comparative effects of oleoyl-estrone and a specific beta3- adrenergic agonist (CL316, 243) on the expression of genes involved in energy metabolism of rat white adipose tissue. Nutr Metab (Lond) 2010; 7: 15.
72. Kryzyanaik, J. Beta 3-adrenergic receptor agnosit crystal forms precessors for the production thereof, and uses thereof. US6689800 (2002).
73. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59(7): 1635-1639.
74. 7TM Pharma's new first-in-class anti-obesity drug completes Phase I/II clinical studies. Available at: http: //www.7tm.com/News/News_Archive.aspx?M=News&PID=45&NewsID=13. (Accessed on: March 20, 2006).
75. Monteiro MP. Anti-ghrelin vaccine for obesity: A feasible alternative to dieting? Expert Rev Vaccines 2011; 10(10): 1363-1365.
76. + Th cell and protective humoral responses. Virology 2002; 302(2): 383-392.
77. Goldstone AP, Thomas EL, Brynes AE, Castroman G, Edwards R, Ghatei MA, et al. Elevated fasting plasma ghrelin in Prader-Willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 2004; 89(4): 1718-26.
78. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346(21): 1623-1630.
79. Lin, J. C.-Y. Methods for treating obesity by administering a trkB antagonist. US7935342 (2011).
80. Cheon HG. Antiobesity effects of melanin-concentrating hormone receptor 1 (MCH-R1) antagonists. Handb Exp Pharmacol 2012; 209: 383-403.
81. Breton C, Schorpp M, Nahon JL. Isolation and characterization of the human melanin concentrating hormone gene and a variant gene. Brain Res Mol Brain Res 1993; 18(4): 297-310.
82. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen ASM, et al. Melanin concentrating hormone 1 receptor- deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002; 99(5): 3240-3245.
83. Houghten, R. A., Dooley, C., Nefzi, A., Wang, Z., Civelli, O., Nagasaki, H. Melanin-concentrating hormone receptor antagonists and methods of use. US20080255218 (2008).
84. Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S, et al. Potent andselective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: Energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009; 86(6): 659-666.
85. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: A preliminary randomized openlabel study. J Clin Psychiat 2007; 68:1226-1229.